Lipoprotein(a): Role in atherosclerosis and new treatment options

Lipoprotein(a): Role in atherosclerosis and new treatment options

Atherosclerosis is a chronic process characterized by inflammation and the progressive accumulation of inflammatory cells and lipids in the blood vessel wall, resulting in narrowing of the blood vessel’s circumference. Treatment of people with dyslipidemia aims to reduce the risk of developing ather...

Full description

Bibliographic Details
Main Authors:	Dragana Tomic Naglic, Mia Manojlovic, Sladjana Pejakovic, Kristina Stepanovic, Jovana Prodanovic Simeunovic
Format:	Article
Language:	English
Published:	Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023-07-01
Series:	Biomolecules & Biomedicine
Subjects:	Lipoprotein(a) (Lp(a)) lipids atherosclerosis major adverse cardiovascular events (MACE) cardiovascular (CV) diseases cardiovascular prevention
Online Access:	https://www.bjbms.org/ojs/index.php/bjbms/article/view/8992

Similar Items

Impact of low-density lipoprotein cholesterol and lipoprotein(a) on mid-term clinical outcomes following coronary artery bypass grafting: A secondary analysis of the DACAB trial
by: Qixiang Yu, et al.
Published: (2023-03-01)

Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment
by: Stamatios Lampsas, et al.
Published: (2023-01-01)

Lipoprotein(a) – Link between Atherogenesis and Thrombosis
by: Danica Labudovic, et al.
Published: (2019-10-01)

Lipoprotein (a), Inflammation, and Atherosclerosis
by: Stefania Angela Di Fusco, et al.
Published: (2023-03-01)

Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option
by: Alessandro Maloberti, et al.
Published: (2022-12-01)

Lipoprotein(a) and atherosclerosis
by: A. V. Tikhonov
Published: (2007-12-01)

Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
by: Henriette Thau, et al.
Published: (2024-02-01)

Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes
by: Michelle D. Kelsey, et al.
Published: (2023-06-01)

Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?
by: Anastasios Makris, et al.
Published: (2023-12-01)

Lipoprotein(a) Modulates Carotid Atherosclerosis in Metabolic Syndrome
by: Anna Laura Cremonini, et al.
Published: (2022-06-01)

Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi‐Ethnic Study of Atherosclerosis
by: Harpreet S. Bhatia, et al.
Published: (2024-02-01)

Lipoprotein(a), its autoantibodies, and circulating T lymphocyte subpopulations as independent risk factors for coronary artery atherosclerosis
by: O I Afanasievа, et al.
Published: (2016-09-01)

Lipoprotein(a): Insights for the Practicing Clinician
by: Pyotr Telyuk, et al.
Published: (2022-06-01)

Editorial: Endogenous and exogenous factors influencing the function and metabolism of lipoproteins
by: Carlo Cervellati, et al.
Published: (2022-12-01)

Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention
by: Zhihao Chen, et al.
Published: (2018-11-01)

Importance of Coagulation Factors as Critical Components of Premature Cardiovascular Disease in Familial Hypercholesterolemia
by: Uffe Ravnskov, et al.
Published: (2022-08-01)

Correlation Between Lipoprotein-Related Phospholipase A2 and Metabolic Syndrome
by: Wang KY, et al.
Published: (2023-12-01)

Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a)
by: Anindita Chakraborty, et al.
Published: (2022-06-01)

Lipoproteína (a) como factor de riesgo independiente de enfermedad cardiovascular aterosclerótica Lipoproten (a) as a risk factor independent of the atherosclerotic cardiovascular disease
by: María Beatriz Cabalé Vilariño, et al.
Published: (2004-06-01)

Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
by: Marlys L. Koschinsky, et al.
Published: (2023-08-01)

Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels
by: Bożena Sosnowska, et al.
Published: (2024-01-01)

Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low‐Density Lipoprotein Cholesterol—The Framingham Heart Study
by: Mehdi Afshar, et al.
Published: (2020-09-01)

Lipoprotein(a) and Low-Molecular-Weight Apo(a) Phenotype as Determinants of New Cardiovascular Events in Patients with Premature Coronary Heart Disease
by: Olga I. Afanasieva, et al.
Published: (2023-10-01)

Epidemiology of atherosclerotic cardiovascular disease in polygenic hypercholesterolemia with or without high lipoprotein(a) levels
by: Pierandrea Vinci, et al.
Published: (2024-01-01)

Evidence and Uncertainties on Lipoprotein(a) as a Marker of Cardiovascular Health Risk in Children and Adolescents
by: Simonetta Genovesi, et al.
Published: (2023-06-01)

The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis
by: Shiyue Wang, et al.
Published: (2022-10-01)

Present and Future of Dyslipidaemia Treatment—A Review
by: Iveta Merćep, et al.
Published: (2023-09-01)

Statins: targeting cardiovascular disease
by: Farouk Mamdoo, et al.
Published: (2017-04-01)

Elevated Lipoprotein (a) and 10-Year Risk of Cardiovascular Disease among Iranian Patients with Bipolar Disorder
by: Shadi Naderyan feli, et al.
Published: (2021-05-01)

Lipoproteins in Cardiovascular Calcification: Potential Targets and Challenges
by: Yin Tintut, et al.
Published: (2018-11-01)

High Lipoprotein(a) Levels as a Predictor of Major Adverse Cardiovascular Events in Hospitalized-Acute Myocardial Infarction Patients
by: Sumarjaya IDGD, et al.
Published: (2020-04-01)

Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?
by: Byambaa Enkhmaa, et al.
Published: (2020-07-01)

Extreme lipoprotein(a) in clinical practice: A cross sectional study
by: Barak Zafrir, et al.
Published: (2023-03-01)

Role of lipoprotein (a) in the development of ischemic stroke and other cardiovascular diseases
by: N. A. Pizov, et al.
Published: (2016-03-01)

Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification
by: Alberto Aimo, et al.
Published: (2020-01-01)

Performance evaluation of five lipoprotein(a) immunoassays on the Roche cobas c501 chemistry analyzer
by: Sara P. Wyness, et al.
Published: (2021-05-01)

Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US study
by: Xingdi Hu, et al.
Published: (2023-06-01)

Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies
by: Harpreet S. Bhatia, et al.
Published: (2022-10-01)

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review
by: Dahlberg S, et al.
Published: (2022-09-01)

Changes in Lipoprotein(a) Levels in People after ST Elevation Myocardial Infarction—The STEMI-Lipids Study
by: Caren Sourij, et al.
Published: (2023-10-01)